Search
Researchers from Memorial Sloan Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
The certification comes after a year in which hundreds of experts worked together to assess standards of care at Hartford HealthCare Cancer Institute.
Cancer biologist Andrea Ventura is the incumbent of a Geoffrey Beene Junior Faculty Chair at the Sloan Kettering Institute, he devotes his research to the nascent field of microRNA expression, seeking to understand how these small RNAs act on genes to promote or suppress cancer.
Memorial Sloan Kettering researchers are investigating the use of tiny particles that behave like sponges to take in drugs and deliver them to tumors.
MSK researchers are developing a new image-generation method for PET scans. It may prove to be quicker and clearer than current scans.
Read about new targets and tactics for treating acute myeloid leukemia.
MSK Kids, the pediatric oncology program at Memorial Sloan Kettering Cancer Center (MSK) has been named one of the best children’s hospitals nationally, according to U.S. News & World Report in its annual “Best Children’s Hospitals” list. MSK Kids is ranked 13th in the nation. MSK Kids has been ranked by U.S. News & World Report for the past 12 years.
A new resource provides a comprehensive list of human proteins that could trigger autoimmune symptoms in ‘long COVID’ patients.
Discover how MSK Kids is using medical play to help children understand treatments and procedures.
Learn about George Bosl, who will become MSK's first ombudsperson.